Active Filter(s):
Details:
The acquisition provides Novartis with full rights to IFM Due's portfolio of STING antagonists, which have the potential to treat an array of serious inflammation-driven diseases characterized by excessive interferon and other pro-inflammatory cytokine signaling.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $835.0 million Upfront Cash: $90.0 million
Deal Type: Acquisition March 13, 2024